Social media

ICH GCP E6(R3) is here. Are you ready? The new guideline introduces sweeping changes to clinical trial operations. In the latest issue of PharmaTimes, ICON’s own Joanne Perry explores why a comprehensive impact assessm...

Biomarkers are redefining clinical trial success in neurodegenerative diseases. Join us for a focused webinar on how imaging, wet, genetic, and digital biomarkers are improving trial accuracy, patient selection, and end...

Join leading experts in #neuroscience and clinical development as they discuss how #biomarkers are transforming trials in Alzheimer’s, Parkinson’s, and related neurodegenerative diseases. This session will cover: - Inte...

We’re looking forward to participating in and hosting C-Path's annual eCOA Consortium EU meeting on October 8–9 at ICON’s Dublin office. This meeting brings together leading eCOA experts to address key industry challen...

We’re looking forward to participating in and hosting C-Path's annual eCOA Consortium EU meeting on October 8–9 at ICON’s Dublin office. This meeting brings together leading eCOA experts to address key industry challen...

LabView360 is ICON’s new digital requisitioning application that streamlines end-to-end sample management—eliminating paper requisition forms, reducing errors, and saving valuable time for sites and sponsors. With digi...

LabView360 is ICON’s new digital requisitioning application that streamlines end-to-end sample management—eliminating paper requisition forms, reducing errors, and saving valuable time for sites and sponsors. With digi...

#RAPSConvergence 2025 is less than a week away! Join ICON in Pittsburgh, 7 - 9 October, for the largest annual event dedicated to regulatory affairs. At booth 409, our team will showcase how we can facilitate end-to-end...

#RAPSConvergence 2025 is less than a week away! Join ICON in Pittsburgh, 7 - 9 October, for the largest annual event dedicated to regulatory affairs. At booth 409, our team will showcase how we can facilitate end-to-end...

A recent peer-reviewed study co-authored by Tim Clark, VP Clinical Sciences at ICON, reviewed UK HRA submissions to evaluate how estimands are being defined post-ICH E9(R1). Findings show that while usage has increased,...

A recent peer-reviewed study co-authored by Dr. Tim Clark, VP Clinical Sciences at ICON, reviewed UK HRA submissions to evaluate how estimands are being defined post-ICH E9(R1). Findings show that while usage has increa...

Integrating modern technologies and scientific advances into cardiovascular outcomes trials can streamline their execution and improve efficiency. Find an overview of tools and strategic approaches sponsors can use to ma...